Cargando…
AZD1480 delays tumor growth in a melanoma model while enhancing the suppressive activity of myeloid-derived suppressor cells
AZD1480 is a potent, competitive small-molecule inhibitor of JAK1/2 kinase which inhibits STAT3 phosphorylation and tumor growth. Here we investigated the effects of AZD1480 on the function of different immune cell populations in a melanoma model. When MO4 tumor-bearing mice were treated with AZD148...
Autores principales: | Maenhout, Sarah K., Four, Stephanie Du, Corthals, Jurgen, Neyns, Bart, Thielemans, Kris, Aerts, Joeri L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4196164/ https://www.ncbi.nlm.nih.gov/pubmed/25149535 |
Ejemplares similares
-
Clinical trials with MRNA electroporated dendritic cells for stage III/IV melanoma patients
por: Wilgenhof, Sofie, et al.
Publicado: (2015) -
Phase II study of autologous mRNA electroporated dendritic cells (TriMixDC-MEL) in combination with Ipilimumab in patients with pretreated advanced melanoma
por: Thielemans, Kris, et al.
Publicado: (2014) -
TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma
por: De Keersmaecker, Brenda, et al.
Publicado: (2020) -
Characterization of CD8(+) T-Cell Responses in the Peripheral Blood and Skin Injection Sites of Melanoma Patients Treated with mRNA Electroporated Autologous Dendritic Cells (TriMixDC-MEL)
por: Benteyn, Daphné, et al.
Publicado: (2013) -
The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma
por: Derenzini, E, et al.
Publicado: (2011)